Investor Service Announcement no. 1/2010

To: NASDAQ OMX Copenhagen Hørsholm, Denmark, February 22, 2010

LifeCycle Pharma A/S to Host Conference Call Announcing Annual Report 2009

LifeCycle Pharma A/S (OMX: LCP) will announce the Annual Report 2009 on
Wednesday February 24, 2010 after 5 PM CET. LCP's Management will host an
accompanying conference call to discuss the financial results on Thursday
February 25, 2010 at 10:00 CET (Denmark) - 09:00 GMT (London).

To access the live conference call, please dial one of the following numbers:
+1 866 966 5335 (US)
+44 (0) 2030 032 666 (UK)
+45 (0) 32 729 273 (DK)

If you cannot access the conference call by mobile phone this could be caused
by some mobile providers blocking the mobile phone from getting access to
certain numbers i.e. toll-free numbers. Therefore please use the DK number
(+45 32 729 273) or the UK number (+44 (0) 2030 032 666) as these numbers are
not toll-free numbers.

An audio replay of the conference call will be available on www.lcpharma.com
from Friday, February 26, 2010 at 17:30 CET (Denmark); 16:30 GMT (London),
11:30 AM ET (New York), 08:30 AM PT (San Francisco), through Thursday, March
25, 2010 by dialing +44 (0) 2081 961 998 (UK) or +1 866 583 1035 (US), and
entering access code
8403264#.

For more information, please contact:
Peter Schøtt Knudsen
Head of Investor Relations
Phone: + 45 2055 3817
Email: [email protected]


About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has a cholesterol-lowering
product, Fenoglide®, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects in preclinical development. LCP is listed on the NASDAQ OMX
Copenhagen under the trading symbol (OMX: LCP).

For further information, please visit www.lcpharma.com.

22022010 lifecycle pharma to host conference call annual report 2009.pdf